IBDEI1XB ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30723,0)
 ;;=E83.42^^123^1583^21
 ;;^UTILITY(U,$J,358.3,30723,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30723,1,3,0)
 ;;=3^Hypomagnesemia
 ;;^UTILITY(U,$J,358.3,30723,1,4,0)
 ;;=4^E83.42
 ;;^UTILITY(U,$J,358.3,30723,2)
 ;;=^5003003
 ;;^UTILITY(U,$J,358.3,30724,0)
 ;;=N25.1^^123^1583^25
 ;;^UTILITY(U,$J,358.3,30724,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30724,1,3,0)
 ;;=3^Nephrogenic Diabetes Insipidus
 ;;^UTILITY(U,$J,358.3,30724,1,4,0)
 ;;=4^N25.1
 ;;^UTILITY(U,$J,358.3,30724,2)
 ;;=^5015616
 ;;^UTILITY(U,$J,358.3,30725,0)
 ;;=E27.49^^123^1583^2
 ;;^UTILITY(U,$J,358.3,30725,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30725,1,3,0)
 ;;=3^Adrenocortical Insufficiency,Other
 ;;^UTILITY(U,$J,358.3,30725,1,4,0)
 ;;=4^E27.49
 ;;^UTILITY(U,$J,358.3,30725,2)
 ;;=^5002743
 ;;^UTILITY(U,$J,358.3,30726,0)
 ;;=E72.09^^123^1583^4
 ;;^UTILITY(U,$J,358.3,30726,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30726,1,3,0)
 ;;=3^Amino-Acid Transport Disorders,Other
 ;;^UTILITY(U,$J,358.3,30726,1,4,0)
 ;;=4^E72.09
 ;;^UTILITY(U,$J,358.3,30726,2)
 ;;=^5002895
 ;;^UTILITY(U,$J,358.3,30727,0)
 ;;=N25.89^^123^1583^23
 ;;^UTILITY(U,$J,358.3,30727,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30727,1,3,0)
 ;;=3^Impaired Renal Tubular Function Disorders,Other
 ;;^UTILITY(U,$J,358.3,30727,1,4,0)
 ;;=4^N25.89
 ;;^UTILITY(U,$J,358.3,30727,2)
 ;;=^5015618
 ;;^UTILITY(U,$J,358.3,30728,0)
 ;;=E26.89^^123^1583^12
 ;;^UTILITY(U,$J,358.3,30728,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30728,1,3,0)
 ;;=3^Hyperaldosteronism,Other
 ;;^UTILITY(U,$J,358.3,30728,1,4,0)
 ;;=4^E26.89
 ;;^UTILITY(U,$J,358.3,30728,2)
 ;;=^5002737
 ;;^UTILITY(U,$J,358.3,30729,0)
 ;;=N25.81^^123^1583^29
 ;;^UTILITY(U,$J,358.3,30729,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30729,1,3,0)
 ;;=3^Secondary Hyperparathyroidism of Renal Origin
 ;;^UTILITY(U,$J,358.3,30729,1,4,0)
 ;;=4^N25.81
 ;;^UTILITY(U,$J,358.3,30729,2)
 ;;=^5015617
 ;;^UTILITY(U,$J,358.3,30730,0)
 ;;=E22.2^^123^1583^28
 ;;^UTILITY(U,$J,358.3,30730,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30730,1,3,0)
 ;;=3^SIADH
 ;;^UTILITY(U,$J,358.3,30730,1,4,0)
 ;;=4^E22.2
 ;;^UTILITY(U,$J,358.3,30730,2)
 ;;=^5002718
 ;;^UTILITY(U,$J,358.3,30731,0)
 ;;=E87.79^^123^1583^10
 ;;^UTILITY(U,$J,358.3,30731,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30731,1,3,0)
 ;;=3^Fluid Overload,Other
 ;;^UTILITY(U,$J,358.3,30731,1,4,0)
 ;;=4^E87.79
 ;;^UTILITY(U,$J,358.3,30731,2)
 ;;=^5003025
 ;;^UTILITY(U,$J,358.3,30732,0)
 ;;=E21.0^^123^1583^27
 ;;^UTILITY(U,$J,358.3,30732,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30732,1,3,0)
 ;;=3^Primary Hyperparathyroidism
 ;;^UTILITY(U,$J,358.3,30732,1,4,0)
 ;;=4^E21.0
 ;;^UTILITY(U,$J,358.3,30732,2)
 ;;=^331439
 ;;^UTILITY(U,$J,358.3,30733,0)
 ;;=E87.71^^123^1583^30
 ;;^UTILITY(U,$J,358.3,30733,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30733,1,3,0)
 ;;=3^Transfusion Associated Circulatory Overload
 ;;^UTILITY(U,$J,358.3,30733,1,4,0)
 ;;=4^E87.71
 ;;^UTILITY(U,$J,358.3,30733,2)
 ;;=^5003024
 ;;^UTILITY(U,$J,358.3,30734,0)
 ;;=D63.1^^123^1584^1
 ;;^UTILITY(U,$J,358.3,30734,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30734,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,30734,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,30734,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,30735,0)
 ;;=I12.0^^123^1584^9
 ;;^UTILITY(U,$J,358.3,30735,1,0)
 ;;=^358.31IA^4^2
